Based on demographics and vaccination rates, the demand for RSV immunizations in the U.S. could eventually exceed $19 billion. But beyond the numbers lies an opportunity for pharmaceutical companies to become an essential resource for consumers and drive positive health outcomes. With only a few immunization options currently approved by the FDA, pharmaceutical giants like…
The post Responding to RSV: How Pharma Brands Can Help 131 Million People appeared first on Terakeet.
